Neurol. praxi. 2011;12(1):28-32

Recent advances in treatment of multiple sclerosis with interferon beta in Czech Republic?

MUDr.Michal Dufek
RS centrum, I. neurologická klinika, LF MU a FN u sv. Anny, Brno

Interferon beta and glatiramer acetate comprise the group of first-choice drugs for the treatment of relapsing-remitting multiple

sclerosis. All the drugs have been shown to have an effect on reducing the relapse rate, reducing the disability rate as well as on

MRI parameters. In the Czech Republic, patients have been treated with these drugs for about 15 years. The basic indication remains

unchanged and the major advances in the past one to two years are: expanding the indication to include clinically isolated

syndrome, reducing the age limit for treatment from 18 to 12 years and the possibility to assess neutralizing antibodies against

interferon beta.

Keywords: multiple sclerosis, clinically isolated syndrome, interferon beta, glatiramer acetate, relapse, neutralizing antibodies

Published: February 18, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Dufek M. Recent advances in treatment of multiple sclerosis with interferon beta in Czech Republic? Neurol. praxi. 2011;12(1):28-32.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Camenga DL, Johnson KP, Alter M, Engelhardt CD, Fishman PS, Greenstein JI, Haley AS, Hirsch RL, Kleiner JE, Kofie VY. Systemic recombinant alfa-2-interferon therapy in relapsing multiple sclerosis. Arch Neurol 1986; 43: 1239-1246. Go to original source... Go to PubMed...
    2. Comi C, Filippi M, Barkhof F, Durelli L, Edan G, Fernandez O, Hartung HP, Seeldrayers P, Soelberg S?rensen P, Rovaris M, Martineli V, Hommes OR and the Early Treatment of MS Study Group. Effect of early interferon treatment on conversion to definite multiple sclerosis; a randomised study. Lancet 2001; 357: 1576-1582. Go to original source... Go to PubMed...
    3. Francis GS, Rice GPA. Alsop JC and the PRISMUS Study Group. Interferon ?-1a in MS: Results following developement of neutralizing antibodies in PRISMS. Neurology 2005; 65: 48-55. Go to original source... Go to PubMed...
    4. Frank JA, Richert N, Bash C, Stone L, Calabresi PA, Lewis B, Stone R, Howard T, McFarland HF. Interferon-beta-1b slows progression of atrophy in RRMS: there zdar follow-up in NAband Nab+ patiens. Neurology 2004; 62: 719-725. Go to original source... Go to PubMed...
    5. Ghezzi A, Amato MP, Annovazzi P, Capobianco M, Gallo P, La Mantia L, Marrosu MG, Martinelli V, Milani N, Moiola L, Patti F, Pozzilli C, Trojano M, Zaffaroni M, Comi G; ITEMS (Immunomodulatory Treatment of Early-onset MS) Group. Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience. Neurol Sci. 2009; 30(3): 193-199. Go to original source... Go to PubMed...
    6. Givannoni G, Barbarash O, Casset-Semanaz F, King J, Pardo G, Simsarian J, Sorensen PS, Stubinski B; on behalf of the Rebif New formulation Study Group. Safety and immunogenicity of a new formulation of interferon ?-1a (Rebif New Formulation) in a phase III study in patiens with relapsing multiple sclerosis: 96-week results. Mult Scler 2008; 00: 1-10. Go to original source...
    7. Goodin DS, Hurwitz BJ, Noronha A. Neutralizing antibodies to interferon ?-1b are not associated with disease worsening in multiple sclerosis. J Int Med Res 2007; 35: 173-187. Go to original source... Go to PubMed...
    8. Hesee D, Fredriksen JL, Koch-Henriksen N, Schreiber K, Stenager E, Heltberg A, Ravnborg M, Bendtzen K, Sellebjerg F, Sorensen PS. Methylprednisolone does not restore biologfical response in multiple sclerosis patiens with neutralizing antibodies against interferon-beta. Eur J Neurol 2009; 16: 43-47. Go to original source... Go to PubMed...
    9. INFB Multiple Sclerosis Study Group. Interferon beta-1b is effective in reapsing-remiting multiple sclerosis. I: Clinical results of a multicenter, randomized, double-blind, placebocontrolled trial. Neurology 1993; 43: 655-661. Go to original source... Go to PubMed...
    10. Jacobs LD, O´Malley, Freeman A, Murawski J, Ekes R. Intrathecal interferon in multiple sclerosis. Arch Neurol 1982; 39(10): 609-615. Go to original source... Go to PubMed...
    11. Jacobs LD, Cookfair D, Rudick RA, Herndon RM, Richert JR, Salazar AM, Fischer JS, Goodkin DE, Granger CV, Simon JH, Alam JJ, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munschauer FE 3rd, Priore RL, Pullicino PM, Scherokman BJ, Whitham RH. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996; 39: 285-294. Go to original source... Go to PubMed...
    12. Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ, Simonian NA, Slasor PJ, Sandrock AW. Intramuscular interferon beta-1a therapy initiated during a first demyelinating even in multiple sclerosis. NEJM 2000; 343: 898-904. Go to original source... Go to PubMed...
    13. Kappos L, Clanet M, Sandberg-Wollheim M, Radue EW, Hartung HP, Hohlfeld R, Xu J, Bennett D, Sandrock A, Goelz S. Neutralizing antibodies and efficacy of interferon ?-1a: a 4 years controlled study. Neurology 2005; 65: 40-47. Go to original source... Go to PubMed...
    14. Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH, Montalbán X, Barkhof F, Radü EW, Bauer L, Dahms S, Lanius V, Pohl C, Sandbrink R; BENEFIT Study Group. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet. 2007; 370(9585): 389-397. Go to original source... Go to PubMed...
    15. Khan OA, Dhib-Jalbut SS. Neutralizing antibodies to interferon beta 1-a and interferon beta 1-b in MS patiens are cross reactive. Neurology 1998; 51: 1698-1702. Go to original source... Go to PubMed...
    16. Malucchi S, Gilli F, Caldano M, Marnetto F, Valentino P, Granieri L, Sala A, Capobianco M, Bertoloto A. Predictive markers for response to interferon therapy in patiens with multiple sclerosis. Neurology 2008; 70: 1119-1127. Go to original source... Go to PubMed...
    17. Panitch HS, Hursch RL, Schnidler J, Johnson KP. Treatment of multiple sclerosis with gamma interferon: Exacerbations associated with activation of the immune system. Neurology 1987; 37: 1097-1102. Go to original source... Go to PubMed...
    18. Polman CH, Bertolotto A, Deisenhammer F, Giovannoni G, Hartung H-P, Hemmer B, Killestein J, McFarland HF, Oger J, Pachner AR, Petkau J, Reder AT, Reingold SC, Schellekens H, S?rensen PS. Recommendations fo clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurol 2010; 9: 740-750. Go to original source... Go to PubMed...
    19. PRISM Study Group. Randomized, double-blind, placebo-controlled study of interferon ?-1a in relapsing-remitting multiple sclerosis. Lancet 1998; 352: 1498-1504. Go to original source...
    20. PRISM Study Group and the University of British Columbia MS/MRI Analysis Group: PRISM-4: long term efficacy of interferon ?-1a in relapsing MS. Neurology 2001; 56: 1628-1636. Go to PubMed...
    21. Ravnborg M, Bendtzen L, Christensen O, Jensen PE, Hesse D, Tovey MG, S?rensen PS. Treatment with azathioprine and cyclic mythylprednisolone had little or no effect on bioactivity in anti-interferon beta antibody-positive patiens with multiple sclerosis. Mult Scler 2009; 15: 323-328. Go to original source... Go to PubMed...
    22. Rot U, Sominanda A, Fogdell-Hahn, Hillert J. Impression of clinical worsening fails to predict interferon-? neutralising antipody status. J Int Med Res 2008; 36: 1418-1425. Go to original source... Go to PubMed...
    23. Sominanda A, Hillert J, Fogdell-Hahn A. In vivo bioactivity of interferon beta in multiple sclerosis patiens with neutralising antibodies is titre-dependent. J Neurol Neurosurg Psychiatry 2008; 79: 57-62. Go to original source... Go to PubMed...
    24. S?rensen PS, Ross C, Clemmesen KM, Bendtzen K, Frederiksen JL, Jensen K, Kristensen O, Petersen T, Rasmussen S, Ravnborg M, Stenager E, Koch-Henriksen N; Danish Multiple Sclerosis StudyGroup. Clinical importace of neutralising antibodies against interferon beta in patiens with relapsing-remitting multiple sclerosis. Lancet 2003; 362: 1184-1191. Go to original source... Go to PubMed...
    25. S?rensen PS, Tschernig T, Mathiesen HK, Langkilde AR, Ross C, Ravnborg M, Bendtzen K. Neutralizing antibodies hamper INF? bioactivity and treatment effect on MRI in patiens with MS. Neurology 2006; 67: 1681-1683. Go to original source... Go to PubMed...
    26. Tomassini V, Paolillo A, Russo P, Giugni E, Prosperini L, Gasperini C, Antonelli G, Bastianello S, Pozzilli C. Predictors of long-term clinical response to interferon beta therapy in relapsing multiple sclerosis. J Neurol 2006; 253: 287-293. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.